Axxam Provides Screening Assays to NIH Chemical Genomics Centre
News Jan 10, 2006
Axxam has announced that it has signed an agreement with the National Institutes of Health ( NIH) to provide access to a selection of screening assays of special interest to the NIH Chemical Genomics Centre ( NCGC) for use in the screening campaigns within the Molecular Libraries Roadmap Initiative.
The screening assays were developed and optimized at Axxam for ultra high-throughput screening (uHTS) applications using ultra sensitive signal detection methods.
"We are very pleased to collaborate with the NIH Chemical Genomics Centre in support of their screening efforts," stated Dr. Lia Scarabottolo, head of cell biology at Axxam.
"We believe that our expertise in the uHTS sector, with a particular emphasis on cell-based assays and their use in large screening campaigns, could provide an important contribution to the future success of the Roadmap initiative at the NCGC."
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018